iSTAR Medical Presents Positive Consistent Results for MINIject® Across Three International Glaucoma Trials
June 08, 2022 07:00 ET
|
iSTAR Medical
For immediate release iSTAR Medical Presents Positive Consistent Results for MINIject® Across Three International Glaucoma Trials Analysis provides further validation of MINIject®’s meaningful and...
iSTAR Medical Presents Positive Consistent Results for MINIject® Across Three International Glaucoma Trials
June 08, 2022 02:00 ET
|
iSTAR Medical
For immediate release iSTAR Medical Presents Positive Consistent Results for MINIject® Across Three International Glaucoma Trials Analysis provides further validation of MINIject®’s meaningful and...
The Worldwide Healthcare Data Collection and Labeling Industry is Expected to Reach $4.5 Billion by 2030
May 30, 2022 07:48 ET
|
Research and Markets
Dublin, May 30, 2022 (GLOBE NEWSWIRE) -- The "Healthcare Data Collection and Labeling Market Size, Share & Trends Analysis Report by Data Type (Image/Video, Audio, Text), by Region (North...
Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy
May 12, 2022 10:00 ET
|
Caribou Biosciences, Inc.
-- 100% ORR (5 of 5 patients) and 80% CR (4 of 5 patients) achieved following 1 dose at the initial dose level in patients with aggressive r/r B-NHL -- -- CB-010 is the 1st allogeneic CAR-T cell...
Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting
May 09, 2022 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., May 09, 2022 ...
Caribou Biosciences to Share CB-010 Initial Clinical Data at the Upcoming European Hematology Association (EHA) 2022 Hybrid Congress
April 25, 2022 16:05 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the...
U.S eClinical Solutions Market Research 2022 Report: Examines the $1.3+ Million Industry
April 12, 2022 06:08 ET
|
Research and Markets
Dublin, April 12, 2022 (GLOBE NEWSWIRE) -- The "eClinical Solutions Market Research Report by Product, by Delivery Mode, by Development Phase, by End-user, by State - United States Forecast to 2027...
Rubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Solid Tumors on April 8, 2022, at 1:15 PM ET
April 07, 2022 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create...
Triphase Accelerator Announces Positive Updated Phase 1 Data with TRPH-222 in Non-Hodgkin’s Lymphoma
February 22, 2022 08:00 ET
|
Triphase Accelerator
High response rates: ORR of 54% and a CR rate of 38%Durable responses: ~25 months median duration of response Favourable safety profile: AEs predominantly low grade, tolerable, easily managed, and...
Sema4 to Participate at Two Upcoming Investor Conferences in February
February 03, 2022 16:05 ET
|
Sema4
STAMFORD, Conn., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will...